Evidence map›Paper›PMID 41949632›Full record

ArticleAntonie van Leeuwenhoek2026

Molecular characterization and immunoinformatics-based design of a multi-epitope vaccine against Staphylococcus nepalensis.

Muhammad Asim, Hotaf Hassan Makki

Abstract read
PubMed Publisher
In one paragraph

Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Muhammad AsimDepartment of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore, Pakistan. muhammadasim4342@gmail.com.
Hotaf Hassan MakkiBiology Department, Faculty of Science, University of Tabuk, 46429, Umluj, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus nepalensis has recently been identified in clinical settings, raising questions regarding its potential role as an emerging opportunistic pathogen. However, no vaccine-based preventive strategy has yet been proposed against this bacterium. The objective of this study was to characterize a clinical isolate using PCR-based molecular identification and to design a rational multi-epitope vaccine candidate against S. nepalensis through an integrated immunoinformatics-driven reverse vaccinology approach. Species-level identification was performed by PCR amplification and sequencing of the 16S rRNA gene. Antigenic proteins lacking predicted allergenic or toxic properties were selected for epitope mapping. Predicted linear B-cell, cytotoxic T lymphocyte, and helper T lymphocyte epitopes were further evaluated for sequence conservancy across available strains to ensure broad-spectrum coverage. Conserved epitopes were assembled into a single construct incorporating β-defensin and a PADRE sequence to enhance immunogenic potential. Structural modeling and validation suggested acceptable stereochemical quality, with 94.8% of residues located in favored regions of the Ramachandran plot. Disulfide engineering was performed to improve structural stability of the vaccine construct. Protein-protein docking computationally predicted favorable binding interactions between the vaccine construct and human TLR2 and TLR4 receptors, with ClusPro docking scores of -1489.2 and -1198.1, respectively. Molecular dynamics simulations suggested dynamic stability of the complexes over a 100 ns trajectory. Immune simulation analyses indicated the potential activation of both humoral and cellular immune responses, including antibody production and cytokine secretion. Codon optimization and in silico cloning suggested possible expression feasibility in Escherichia coli. Collectively, this study presents a computational framework for multi-epitope vaccine design against S. nepalensis, and the findings require experimental validation to confirm biological efficacy and immunogenicity.

Indexed as

EpitopesStaphylococcal InfectionsStaphylococcal VaccinesStaphylococcusEpitope MappingEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansImmunoinformaticsMolecular Docking SimulationProtein Subunit VaccinesReverse VaccinologyRNA, Ribosomal, 16SToll-Like Receptor 2Toll-Like Receptor 4EpitopesEpitopes, B-LymphocyteEpitopes, T-LymphocyteProtein Subunit VaccinesRNA, Ribosomal, 16SStaphylococcal VaccinesTLR2 protein, humanTLR4 protein, humanToll-Like Receptor 2Toll-Like Receptor 4AlphaFold 3Molecular dockingMolecular dynamics simulationsMulti-epitope vaccinePCRStaphylococcus nepalensis

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.